Veteran | Malignant neoplasm of skin High risk | Keratinocyte Carcinoma Quantity | Keratinocyte Carcinoma Face | Keratinocyte Carcinoma Ear
Item
veteran who is at high risk for developing skin cancer defined as 2 keratinocyte carcinomas in the past 5 years, at least one of which was located on the face or ears
boolean
C0042610 (UMLS CUI [1])
C0007114 (UMLS CUI [2,1])
C0332167 (UMLS CUI [2,2])
C0022567 (UMLS CUI [3,1])
C0007097 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0022567 (UMLS CUI [4,1])
C0007097 (UMLS CUI [4,2])
C0015450 (UMLS CUI [4,3])
C0022567 (UMLS CUI [5,1])
C0007097 (UMLS CUI [5,2])
C0521421 (UMLS CUI [5,3])
Lacking Able to speak English Language
Item
participants who are unable to speak english
boolean
C0332268 (UMLS CUI [1,1])
C0564215 (UMLS CUI [1,2])
C0376245 (UMLS CUI [1,3])
Keratinocyte Carcinoma
Item
participants with kc at randomization
boolean
C0022567 (UMLS CUI [1,1])
C0007097 (UMLS CUI [1,2])
Field therapy Actinic keratosis Face | Field therapy Actinic keratosis Ear | Fluorouracil Cream | Cold Therapy Actinic keratosis Lesion | Fluorouracil, Systemic | Capecitabine Oral Product | Xeloda Oral Product | Hypersensitivity Sunscreening Agents | Triamcinolone allergy | Fluorouracil allergy
Item
participants currently using or having used field therapy for aks on the face or ears in the past 3 years. the vast majority of these field treatments would have been with 5-fu cream. we will allow recent use of therapies that are applied to individual ak lesions (e.g. cryotherapy), but not those that were used on an entire area (field) in the study treatment area participants currently using or having used systemic 5-fluorouracil or oral capecitabine (xeloda) within the past 3 years participants with known allergy to sunscreen, triamcinolone and/or 5-fluorouracil.
boolean
C0205146 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0022602 (UMLS CUI [1,3])
C0015450 (UMLS CUI [1,4])
C0205146 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0022602 (UMLS CUI [2,3])
C0521421 (UMLS CUI [2,4])
C0016360 (UMLS CUI [3,1])
C1378128 (UMLS CUI [3,2])
C0010412 (UMLS CUI [4,1])
C0022602 (UMLS CUI [4,2])
C0221198 (UMLS CUI [4,3])
C0720482 (UMLS CUI [5])
C3213270 (UMLS CUI [6])
C3240162 (UMLS CUI [7])
C0020517 (UMLS CUI [8,1])
C0038818 (UMLS CUI [8,2])
C0571619 (UMLS CUI [9])
C0570698 (UMLS CUI [10])
Keratinocyte Carcinoma Due to Causes Special | Exception Exposure to Ultraviolet Rays
Item
exclusions 6-l0: we will exclude the small proportion who get their kcs for special reasons other than ultraviolet radiation exposure (see list below), since that etiologic difference, which is associated with a prognostic difference, could be associated with a biologic difference in response to chemoprevention efforts. these will include:
boolean
C0022567 (UMLS CUI [1,1])
C0007097 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0015127 (UMLS CUI [1,4])
C0205555 (UMLS CUI [1,5])
C1705847 (UMLS CUI [2,1])
C0332157 (UMLS CUI [2,2])
C0041625 (UMLS CUI [2,3])
Solid organ transplant Recipient | Kidney Transplantation | Transplantation of liver | Heart Transplantation
Item
solid organ transplant recipients, such as renal, hepatic, or cardiac transplant patients
boolean
C0730400 (UMLS CUI [1,1])
C1709854 (UMLS CUI [1,2])
C0022671 (UMLS CUI [2])
C0023911 (UMLS CUI [3])
C0018823 (UMLS CUI [4])
Genetic Diseases Associated with Heightened Cancer Risk
Item
individuals with genetic disorders associated with very high cancer risk such as:
boolean
C0019247 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C1512362 (UMLS CUI [1,3])
Basal Cell Nevus Syndrome
Item
basal cell nevus syndrome
boolean
C0004779 (UMLS CUI [1])
Erythrodysplasia | Other Coding
Item
erythrodysplasia verruciformis
boolean
C2987488 (UMLS CUI [1])
C3846158 (UMLS CUI [2])
Xeroderma Pigmentosum
Item
xeroderma pigmentosum
boolean
C0043346 (UMLS CUI [1])
arsenic exposure
Item
arsenic exposure
boolean
C0238690 (UMLS CUI [1])
PUVA
Item
puva (psoralen plus uva) treatment
boolean
C0853073 (UMLS CUI [1])
Lymphoma, T-Cell, Cutaneous
Item
cutaneous t-cell lymphoma
boolean
C0079773 (UMLS CUI [1])
Therapeutic radiology procedure Face | Radiotherapy to ear
Item
prior or current radiation therapy to the face and/or ears.
boolean
C1522449 (UMLS CUI [1,1])
C0015450 (UMLS CUI [1,2])
C0948311 (UMLS CUI [2])
Exclusion Criteria Additional
Item
additional exclusions (12-15) are:
boolean
C0680251 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
Mortality High risk Very | Life Expectancy | Comorbidity | Neoplasm Metastasis | COPD
Item
those who, in the opinion of the recruiting investigator, have very high mortality risk at randomization (less than 50% chance of surviving 4 years) due to co morbid illness such as metastatic cancer or copd.
boolean
C0026566 (UMLS CUI [1,1])
C0332167 (UMLS CUI [1,2])
C0442824 (UMLS CUI [1,3])
C0023671 (UMLS CUI [2])
C0009488 (UMLS CUI [3])
C0027627 (UMLS CUI [4])
C0024117 (UMLS CUI [5])
Childbearing Potential Pregnancy Test Initial | Childbearing Potential Contraceptive methods
Item
for women of childbearing potential an initial pregnancy test and ongoing birth control will be required for participation.
boolean
C3831118 (UMLS CUI [1,1])
C0032976 (UMLS CUI [1,2])
C0205265 (UMLS CUI [1,3])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Dihydropyrimidine Dehydrogenase Deficiency | Toxicity Increased Due to Systemic Fluorouracil
Item
patients with known dihydropyrimidine dehydrogenase (dpd) enzyme deficiency by self report or noted in the medical record (they have increased toxicity from systemic 5-fu, although screening for this is not part of dermatologic practice and will not be part of this study).
boolean
C1959620 (UMLS CUI [1])
C0600688 (UMLS CUI [2,1])
C0205217 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0720482 (UMLS CUI [2,4])
Methotrexate | Severe reaction 5-FU Topical
Item
patients on methotrexate (these will constitute about 1% of potentially eligible individuals) because they may have more severe reactions to topical 5-fu.
boolean
C0025677 (UMLS CUI [1])
C3242604 (UMLS CUI [2,1])
C0016360 (UMLS CUI [2,2])
C1710439 (UMLS CUI [2,3])